Role of zoledronic acid in the prevention and treatment of osteoporosis
Agnès Räkel, Andrée Boucher, Louis-Georges Ste-MarieEndocrinology, Department of Medicine. Centre de recherche du CHUM, Université de Montréal, Montréal, QC, CanadaAbstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast&...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ab0974cfecea4416af1a7e6ac9610e07 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Agnès Räkel, Andrée Boucher, Louis-Georges Ste-MarieEndocrinology, Department of Medicine. Centre de recherche du CHUM, Université de Montréal, Montréal, QC, CanadaAbstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol.Keywords: zoledronic acid, osteoporosis, elderly |
|---|